

## Special Issue

# Innovation in Antibody-Drug Conjugates (ADCs)

### Message from the Guest Editors

The recent approval by many regulatory boards of various Antibody-drug conjugates (ADC) had a dramatic improvement in the outcome of cancer patients. Since the first approval of ADC more than 20 years ago, there has been a major effort to improve its efficacy of ADC. This overall efficacy ADC is defined by antibody, linker, and payload. Further, these factors will impact the overall toxicities. This Special Issue of ADC allows us to present the latest research related to ADC and collectively show the future of ADC research direction. We are pleased to invite you to address the innovative approach to treating cancer by ADC, novel modification, and the translational and clinical impact of ADC in cancer management.

Prof.

### Guest Editors

Prof. Dr. Naoto T. Ueno

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Prof. Dr. Jennifer Maynard

1. Department of Biochemistry, The University of Texas at Austin, Austin, TX 78712, USA

2. McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/154821](https://mdpi.com/si/154821)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)